Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model.

IF 3.1 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Intervention and Therapeutics Pub Date : 2024-07-22 DOI:10.1007/s12928-024-01023-3
Sho Torii, Akiko Yamamoto, Ayako Yoshikawa, Linhai Lu, Makoto Sasaki, Shoko Obuchi, Akira Wada, Hideo Tsukamoto, Gaku Nakazawa
{"title":"Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model.","authors":"Sho Torii, Akiko Yamamoto, Ayako Yoshikawa, Linhai Lu, Makoto Sasaki, Shoko Obuchi, Akira Wada, Hideo Tsukamoto, Gaku Nakazawa","doi":"10.1007/s12928-024-01023-3","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of the study is to investigate the safety, feasibility, and degradation profile of a novel Mg alloy-based bioresorbable coronary scaffold (JFK-PRODUCT BRS) with thin struts (110 μm). Polymer- or Mg alloy-based BRSs have not replaced nondegradable metal stents because of the higher prevalence of scaffold thrombosis and restenosis in clinical practice; these poor clinical outcomes were due to inadequate scaffold designs, including thick struts (more than 150 μm) and their inappropriate degradation processes. Fourteen healthy pigs received 17 JFK-PRODUCT BRSs in the coronary arteries and were sacrificed at 1, 6, 12, 18, and 26 months after implantation. Angiography, optical coherence tomography, microfocus X-ray computed tomography (µCT), scanning electron microscopy with energy-dispersive X-ray spectrometry (SEM-EDX), and histopathological evaluation were performed. The JFK-PRODUCT had a median percent late recoil of 11.28% at 1 month. The µCT observation confirmed that scaffold discontinuity reached 64.8% at 12 months with increased scaffold inner area thereafter, suggesting artery positive remodeling. The inflammation was mild, peaked at 18 months, and decreased thereafter. The SEM-EDX analysis demonstrated gradual degradation of the scaffold with formation of inorganic deposits, presumed to be calcium phosphates. It also revealed the disappearance of calcium phosphates at 26 months, achieving almost complete replacement of the scaffold by biocomponents. The current study demonstrated the safety and feasibility of JFK-PRODUCT with a lower acute recoil rate despite its thin struts. The scaffolds were almost completely disappeared at 26 months after implantation.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-024-01023-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The objective of the study is to investigate the safety, feasibility, and degradation profile of a novel Mg alloy-based bioresorbable coronary scaffold (JFK-PRODUCT BRS) with thin struts (110 μm). Polymer- or Mg alloy-based BRSs have not replaced nondegradable metal stents because of the higher prevalence of scaffold thrombosis and restenosis in clinical practice; these poor clinical outcomes were due to inadequate scaffold designs, including thick struts (more than 150 μm) and their inappropriate degradation processes. Fourteen healthy pigs received 17 JFK-PRODUCT BRSs in the coronary arteries and were sacrificed at 1, 6, 12, 18, and 26 months after implantation. Angiography, optical coherence tomography, microfocus X-ray computed tomography (µCT), scanning electron microscopy with energy-dispersive X-ray spectrometry (SEM-EDX), and histopathological evaluation were performed. The JFK-PRODUCT had a median percent late recoil of 11.28% at 1 month. The µCT observation confirmed that scaffold discontinuity reached 64.8% at 12 months with increased scaffold inner area thereafter, suggesting artery positive remodeling. The inflammation was mild, peaked at 18 months, and decreased thereafter. The SEM-EDX analysis demonstrated gradual degradation of the scaffold with formation of inorganic deposits, presumed to be calcium phosphates. It also revealed the disappearance of calcium phosphates at 26 months, achieving almost complete replacement of the scaffold by biocomponents. The current study demonstrated the safety and feasibility of JFK-PRODUCT with a lower acute recoil rate despite its thin struts. The scaffolds were almost completely disappeared at 26 months after implantation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型镁合金基生物可吸收冠状动脉支架在猪冠状动脉模型中的降解。
这项研究的目的是调查一种基于镁合金的新型生物可吸收冠状动脉支架(JFK-PRODUCT BRS)的安全性、可行性和降解情况,该支架的支撑杆很细(110 μm)。基于聚合物或镁合金的生物可吸收支架尚未取代不可降解的金属支架,因为在临床实践中支架血栓形成和再狭窄的发生率较高;这些不良的临床结果是由于支架设计不当造成的,包括厚支架(超过 150 μm)及其不适当的降解过程。14 头健康猪在冠状动脉中植入了 17 个 JFK-PRODUCT BRS,并在植入后 1、6、12、18 和 26 个月处死。对其进行了血管造影、光学相干断层扫描、微聚焦 X 射线计算机断层扫描(µCT)、扫描电子显微镜与能量色散 X 射线光谱分析(SEM-EDX)和组织病理学评估。1 个月后,JFK-PRODUCT 的中位晚期反冲率为 11.28%。µCT观察证实,12个月时支架不连续性达到64.8%,此后支架内部面积增加,表明动脉正向重塑。炎症很轻微,在 18 个月时达到高峰,之后有所减轻。SEM-EDX 分析显示支架逐渐降解,形成无机沉积物,推测为磷酸钙。该分析还显示,在 26 个月时,磷酸钙消失,支架几乎完全被生物成分取代。目前的研究证明了 JFK-PRODUCT 的安全性和可行性,尽管它的支架很薄,但急性反冲率较低。支架在植入 26 个月后几乎完全消失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Intervention and Therapeutics
Cardiovascular Intervention and Therapeutics CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
6.30
自引率
12.50%
发文量
68
期刊介绍: Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.
期刊最新文献
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024. RAPID software analysis and mechanical thrombectomy for periprocedural ischemic stroke after transcatheter aortic valve implantation. Utilization of proximal cap disruption using intravascular lithotripsy for severely calcified bifurcated-CTO entry. Hemodynamic effect of supra-annular implantation of SAPIEN 3 balloon expandable valve. Clinical outcomes of endovascular therapy for chronic limb-threatening ischemia in renal transplant recipients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1